LOGIN
Zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis
May 2013
Zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
Lancet. 2009 Apr 11;373(9671):1253-63Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
833 patients, undergoing treatment with glucocorticoids for 12 months, were randomized to receive zoledronic acid or risedronate in this double blind, double dummy trial. This study assessed the non-inferiority of one injection of zoledronic acid for the prevention and treatment of glucocorticoid induced osteoporosis compared to the daily oral risedronate dosage. Following the one year treatment p...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.